Perrigo ingenol mebutate compared with reference product in actinic keratosis
Actinic Keratosis
Enrolment: 519 · Results not recorded
Loading the evidence…
Drug · Unknown (ChEMBL mechanism record mec_id 2174; sole reference is the FDA label for Picato)
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Actinic Keratosis
Enrolment: 519 · Results not recorded
Actinic Keratosis
Enrolment: 463 · Results not recorded
Actinic Cheilitis
Enrolment: 0 · Results not recorded
Actinic Keratosis
Enrolment: 200 · Results not recorded
Actinic Keratosis
Enrolment: 16 · Results not recorded
Carcinoma
Enrolment: 24 · Results not recorded
Superficial Basal Cell Carcinoma
Enrolment: 117 · Results not recorded
Actinic Keratosis
Enrolment: 12 · Results not recorded
Actinic Keratosis
Enrolment: 20 · Results not recorded
Actinic Keratosis
Enrolment: 0 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Chronic UVB irradiation producing photodamaged skin with mutant p53 keratinocyte patches and subsequent skin lesions
Topical 0.05% ingenol mebutate reduced emergent skin lesions by approximately 70% and mutant p53 keratinocyte patches by approximately 70% versus placebo, with transient epidermal cell death, inflammation and eschar that resolved over several weeks.
Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.